Novartis Investigative Site

Geißen

0 studies enrolling now · 2 studies all time

What they study most

Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis With Active Flare

Studies at this site

• Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) — Stopped early
• Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) — Completed